Claims
- 1. A composition comprising an isolated polypeptide, wherein the polypeptide is identified as Adlican or a functional portion thereof or a polypeptide which is at least substantially homologous or identical thereto and a physiologically acceptable excipient.
- 2. The composition according to claim 1, wherein the polypeptide is a human Adlican or a functional portion thereof.
- 3. The composition according to claim 2, wherein the functional portion comprises a polypeptide having a molecular weight of 10 kD to 30 kD.
- 4. The isolated polypeptide according to claim 1, wherein the the functional portion comprises a polypeptide having a molecular weight of about 25 kD.
- 5. A composition comprising one or more isolated polypeptides according to claim 1.
- 6. An antibody elicited by a polypeptide according to claim 1 or a functional portion thereof.
- 7. A composition comprising the antibody according to claim 6 or a functional portion thereof.
- 8. A method for treating or preventing osteoporosis, or for fracture healing, bone enlongation, or periodontosis in a subject, comprising administering to the subject an effective amount of the isolated polypeptide according to claim 1.
- 9. A method of treating or preventing osteoarthritis, osteopetrosis, or osteosclerosis, comprising administering to a subject an effective amount of a chemical or neutralizing monoclonal antibodies which inhibit the activity of the polypeptide according to claim 1.
- 10. A composition comprising an isolated nucleic acid molecule encoding the polypeptide according to claim 1 and a physiologically acceptable excipient.
- 11. A composition comprising a vector comprising an isolated nucleic acid molecule encoding the polypeptide according to claim 1 and a physiologically acceptable excipient.
- 12. A method for preventing, treating or controlling osteoporosis, or for fracture healing, bone enlongation or osteopenia, periodontosis, or low bone density or other conditions involving mechanical stress or a lack thereof in a subject, comprising administering to the subject an effective amount of a composition as claimed in claim 11.
- 13. A method for preventing, treating or controlling osteoporosis, or for fracture healing, bone enlongation or osteopenia, periodontosis, bone fractures or low bone density or other factors causing or contributing to osteoporosis or symptoms thereof or other conditions involving mechanical stress or a lack thereof in a subject, comprising administering the vector as claimed in claim 12 to the subject.
- 14. A method for preventing, treating or controlling osteoporosis, or for fracture healing, bone enlongation or osteopenia, periodontosis, bone fractures or low bone density or other factors causing or contributing to osteoporosis or symptoms thereof or other conditions involving mechanical stress or a lack thereof in a subject, comprising administering an isolated nucleic acid molecule encoding the polypeptide according to claim 1, or a functional portion thereof or a polypeptide comprising an expression product of the gene or functional portion of the polypeptide or an antibody to the polypeptide or a functional portion of the antibody.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the priority of U.S. patent application Ser. No. 09/729,485 filed Dec. 4, 2000 which claims the priority of U.S. Provisional application Ser. No. 60/207,821, filed May 30, 2000 and U.S. Ser. No. 09/632, 862, filed Aug. 4, 2000.
[0002] Reference is also made to U.S. Provisional application Ser. No. 60/084,944, filed May 11, 1998; and the full U.S. utility application, Ser. No. 09/309,862, filed May 11, 1999, and claiming priority from U.S. Provisional application Ser. No. 60/084,944 (herein “the May 14, 1999 Einat et al. full U.S. utility application”); and U.S. Ser. No. 09/312,216, filed, May 14,1999; and U.S. Provisional application Ser. No. 60/085,673, filed May 15, 1998; U.S. Provisional application Ser. No. 60/085,673, filed May 15, 1998; U.S. Provisional application Ser. No. 60/207, 821, filed May 30, 2000; U.S. Ser. No. 09/312,216, filed, May 14, 1999; U.S. Provisional application Ser. No. 60/084,944; and the May 11, 1999 Einat et al. full U.S. utility application; as well as each document or reference cited in these applications, are hereby expressly incorporated herein by reference. Documents or references are also cited in the following text and, each of these documents or references (“herein-cited documents or references”), as well as each document or reference cited in each of the herein-cited documents or references, are hereby expressly incorporated herein by reference. It is explicitly stated that the inventive entity of the May 11, 1999 Einat et al. full U.S. utility application is not another or others as to the inventive entity of this application; and, that the inventive entity of the present application is not another or others as to the inventive entity of the May 11, 1999 Einat et al. full U.S. utility application.
Provisional Applications (3)
|
Number |
Date |
Country |
|
60207821 |
May 2000 |
US |
|
60084944 |
May 1998 |
US |
|
60085673 |
May 1998 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09729485 |
Dec 2000 |
US |
Child |
09802318 |
Mar 2001 |
US |